cse:luv love pharma – driving a sexual health and

The LimitlessVPN Miner provides an excellent entry point into the

world of crypto mining…PAGE 20

OPENING UP LARGE MARKETS WITH INNOVATIVE PRODUCTS

CSE:LUV

FSD – A MAJOR ISSUE OVERLOOKED BY

THE MAINSTREAM

PAGES 4-5

A NATURAL SOLUTION THAT HELPS THE BODY

TO HELP ITSELF

PAGES 6-7

PAGES 2-3

LOVE PHARMA – DRIVING A SEXUAL HEALTH AND WELLBEING REVOLUTION

BROUGHT TO YOU BY VALUE THE MARKETS

LOVE PHARMA – DRIVING A SEXUAL HEALTH AND WELLBEING REVOLUTION

OPENING UP LARGE MARKETS WITH INNOVATIVE WELLBEING PRODUCTSOn first reflection, LOVE Pharma might seem like a company only concerned with sexual health and wellbeing...

But, as you’ll see in this report, when you scratch just below the surface you find a team driving innovation in a much broader market.

Both of these leading products could generate transformational returns for LOVE Pharma.

Of course, that’s not to say the opportunity in the sexual health and wellbeing space is insignificant.

Quite the opposite – it’s massive.

And as we’ll explore, the ground-breaking women’s health product LOVE Pharma is looking to bring to market immediately could well lead it to dominate an overlooked part of the space expected to grow by more than $200m between 2021 and 2025.

In addition, the company has also owns intellectual property to a product that could give hope to millions of couples seeking a way to conceive children without resorting to expensive IVF treatments.

A SEXUAL HEALTH AND WELLBEING REVOLUTION 2

Both could be transformational for LOVE Pharma and its investors.

But, as we say, they are really only the beginning.

You see, the firm is also developing and readying to bring to market a potentially game-changing new way to use CBD and THC that could help with a whole range of health and wellbeing issues.

That might sound a little random given the nature of LOVE Pharma’s other products.

But, as we’ll explore in this report, everything is in fact linked by the company’s underlying science, which its expert partners have been developing and testing behind the scenes.

It all makes for a very exciting story that is gathering huge momentum and becoming an exciting opportunity for early investors looking to diversify their portfolios.

Indeed, the well-funded company has just recently listed on the Canadian Securities Exchange under the symbol LUVE and has plans to pursue US and German listings moving forward.

Not only that but the group behind the firm are well respected and proven to have what it takes to turn small start-ups into serious players.

But, as you’ll see, this excellent opportunity really starts with the provision of a long-overdue solution to a long-overlooked problem.

And, as such, that’s the area we’ll explore in depth first...


FSD – A MAJOR ISSUE OVERLOOKED BY THE MAINSTREAMWithout a doubt, the issue LOVE Pharma is looking to help solve with the first product it’s bringing to market is a tough one for many to talk about.

We’re referring here to female sexual dysfunction, or FSD as it’s commonly known.

FSD can take many forms, but the most common symptom is vaginal dryness, which can become a greater problem with age.

Not only does this cause general discomfort, but it can also reduce the capacity for orgasm and the desire for intimacy altogether. As any woman who has suffered from such symptoms knows, it is not a pleasant experience.

Moreover, it’s an issue that has gone overlooked for far too long, especially when you consider the sheer number of women it affects.

In fact, though it’s hard to put exact figures on it because FSD takes so many different forms, it’s estimated that between 30-50% of women in the US alone experience some form of the disorder.

That is a staggering number and, of course, it represents a huge potential consumer base.

It’s estimated that up to half of all US women suffer from some form of FSD.


Indeed, where the market for male sexual dysfunction is already thought to generate a massive $2 billion annually…

It’s thought the market for FSD treatments could become up to three times larger.

We’re talking about an almost untapped market here worth between $4-6 billion a year that is thought to be growing at a rate of 35% annually.

And, though it’s a sensitive subject, there is no ignoring the fact that it could present LOVE Pharma with a huge opportunity for revenues.

And that’s before we’ve even explored the other ways LOVE Pharma is looking to increase its reach into not just sexual issues, but health and wellbeing more generally.

Still, let’s start by digging a little deeper into the science behind this first product, because, as you’ll see, it actually unlocks a much broader opportunity...

It’s thought the market for FSD treatments could eventually be several times the size of the one for male sexual dysfunction.


And most importantly, it’s extremely effective at doing so.

A NATURAL SOLUTION THAT HELPS THE BODY TO HELP ITSELF

However, many are lubricants made with artificial petrochemicals.

This means that, while they might seem to solve the problem in the short term, they can cause further issues like bacterial infections.

LOVE Pharma identified this problem and purchased the rights to a topical gel that swaps petrochemicals for a patented blend of natural ingredients already cleared by the Food and Drug Administration.

Though there has not been nearly enough work done in the area of FSD, some partial treatments do already exist in the market.

The two most critical components here are menthol and an amino acid called L-arginine.

You see, extensive testing has found that these two ingredients work in harmony to stimulate the body.

This is crucial.

So, rather than acting as a lubricant itself, LOVE Pharma’s branded product—known as Bloom—effectively works with the body and enables it to produce its own natural lubricant.


In fact, a recent study found that 80% of women were able to lubricate naturally more quickly when using

Bloom. Likewise, in that same survey, 70% said the lubrication was of a higher quality.

These results are hugely encouraging and show just how popular Bloom could be when rolled out through the many distribution channels LOVE Pharma is establishing.

Not only that, but it’s also worth pointing out that the study found that more than two-thirds of women who used Bloom enjoyed a better, more intense sexual experience.

As you’ll see in the next section of this report, this means the science here can be applied to a much wider range of issues and products to treat those issues.

But in the first instance, it’s thanks to this more natural approach to lubrication that LOVE Pharma is set to not so much disrupt the FSD treatment market but provide a whole new way of solving the very serious problem.

However, as we pointed out in the introduction, there is another angle here that will be of great interest to investors who are already familiar with the use of cannabis-derived ingredients in the booming health and wellbeing space.

You see, though the Bloom product has already been found to be extremely effective, LOVE Pharma and its partners are not finished with exploring ways to make it even more useful for women.

Specifically, they plan to release versions containing CBD and/or THC.

Early testing—as reported in a special white paper—has found that CBD can significantly promote sexual arousal in the brain.

So, when working in conjunction with the already-stimulating effects of menthol and L-arginine, this could help to increase lubrication and reduce the symptoms of FSD even further.

It’s great news where treating FSD is concerned.

But astute investors will also recognize that it’s a hugely significant potential crossover with the rising popularity of products that exploit the many benefits of CBD and THC.

Indeed, keep that thought in your mind, as we’ll explore it again shortly. But before we do, we mentioned that Bloom is only the first product LOVE Pharma plans to go live with.

As you’ll see next, there are several more in the pipeline...


A BROAD RANGE OF PRODUCTS LOCKED, LOADED, AND READY FOR RELEASEBloom will be the first product LOVE Pharma takes to the market.

It addresses FSD in a natural and unique way, while the addition of ingredients like CBD and THC stands to increase its effectiveness even more moving forward.

The immediate and long-term revenue potential of this range alone clearly stands to be huge for LOVE Pharma.

But the reality is that this firm’s exposure to the sexual wellness market extends beyond Bloom alone.

The company has also exclusively licensed several complementary products targeting additional issues in the market.

And now, they are locked, loaded, and ready for release.

However, rather than flood the market with all of its products at once…

LOVE Pharma is staggering their launch to maximize their individual impact.

It’s a smart, tried and tested move used by companies the world over.

Just look at Coca-Cola as an example.

If the soft drinks giant were to release all of its brands and flavors at once, it would overwhelm consumers. Sales of each line could suffer as a result.

That’s why, instead, it has released its products gradually over the years, giving those in the soft drinks market the opportunity to absorb each one fully.

In the same way, LOVE Pharma’s wider sexual wellness range

presents numerous individual revenue opportunities that will

each benefit from the most strategic release possible.

So, what exactly does the firm have in store?


Well, among its most interesting future opportunities is a moisturizing vaginal gel called ToConceive, which targets the fertility market.

And given the size of this space, it could ultimately become the jewel in the company’s crown.

Indeed, around 7.4 million couples globally have trouble getting pregnant or sustaining a pregnancy. It’s a huge potential market just crying out for a novel solution.

And this is exactly what ToConceive provides.

You see, in 75% of cases of unexplained infertility among healthy couples, insufficient natural

lubrication has been identified as the primary issue.

ToConceive uses a similar combination of menthol and L-arginine as Bloom to help increase natural lubrication and also the production of a protein called ‘albumin’.

This, in turn, increases the chances of conception.

What’s more, some lubricants on the market have actually been found to damage sperm and reduce the chances of conception. LOVE Pharma’s natural solution avoids that problem by supporting the production of entirely natural lubrication.


The firm will also use these ingredients in a range of natural and patented supplements aimed specifically at enhancing desire and sexual performance in both women and men.

But, as you’ll see in the next section, LOVE Pharma is also taking its science beyond the sexual wellness space and into another sector entirely…

It also provides an alternative, cheaper step for healthy couples ahead of resorting to IVF treatments, which can cost thousands and can take a long time. Indeed, a cycle of ToConceive costs just $100 and can be used immediately.

Moving on, and another interesting product in LOVE Pharma’s roster is its Male Enhancement Topical.

This gel is applied to the penis daily for 90 days and is clinically proven to increase overall length and girth by nearly a third by increasing blood flow but has not yet undergone the FDA approval process, which presents a unique value proposition if the company pursues it.

The key ingredients?

You guessed it – menthol and L-arginine.

HAVE TROUBLE GETTING PREGNANT

OR SUSTAINING A PREGNANCY

1 in 8 COUPLES


A REVOLUTIONARY CBD PRODUCT WITH HUGE UPSIDE POTENTIALLOVEPharma’s second launch product alongside its Bloom arousal gel is a very different beast.

Indeed, the firm is also taking what is known as a muco-adhesive strip to the market.

In basic terms, this is a small dissolvable film that is placed under the tongue. It’s called the “sub-lingual” delivery method, and it’s not dissimilar to the dental strips many use to freshen their breath.

However, rather than mint alone, LOVEPharma’s product contains menthol, L-arginine, and CBD.

Why?

Well, under the tongue, the strip gently adheres to the “mucal membrane”. The ingredients are then absorbed by the body and enter the bloodstream where they can take effect.


The use of a mucoadhesive that is impregnated with Menthol and L-Arginine results in improved retention time of the delivered cannabinoid, as well as improved bioavailability, increased Cmax, and decreased Tmax compared to standard intra-oral absorption of cannabinoids.

“

”

There’s a reason sub-lingual strips are so popular in the pharma world – they are known to be extremely effective and very quick to act.

So, when you also add into the mix menthol and L-arginine – both

proven to increase the uptake of chemicals into the body – you’re looking at an extremely effective CBD product.

Indeed, as one scientific white paper summarizes…


Bottom line is, studies have shown that the only method of CBD delivery that even comes close to LOVE Pharma’s muco-adhesive strips in terms of absorption speed, level of impact, and duration of impact is direct inhalation.

Other oral delivery systems such as CBD oils and CBD gummies don’t even come close.

What’s more, the strips—which will be released with the brand name “Aurelief”-- have the added benefit of being much more consumer-friendly than CBD inhalation.

Indeed, placing a strip under the tongue is both more discrete and has a more “clinical” feeling than smoking a vape pen.

Given the rapid growth on offer in the global CBD market, which is on track to surpass a $20 billion valuation by 2024…

The immediate revenue potential that Aurelief presents to LOVE Pharma is huge.

But, as with its focus on the sexual wellness market, the firm refuses to sit on its laurels here.

Indeed, it is developing a version of the strip containing THC for release into market where the substance is permitted legally.

It is even developing a version containing psilocybin – the active ingredient in “magic mushrooms”.

Given the psychedelics market is poised to reach a $6.9 billion valuation by 2027 from $2 billion in 2020 as more and more jurisdictions ease their legal stances towards the hallucinogenic compounds…

LOVE Pharma is primed to crack yet another huge untapped opportunity.

The global CBD market is on track to surpass a $20 billion valuation by 2024.


A PROVEN TEAM PROVIDING INVESTORS WITH YET ANOTHER GREAT WAY TO DIVERSIFY THEIR PORTFOLIOBefore summarizing the LOVE Pharma opportunity, it’s worth talking briefly about another company altogether.

You may or may not have heard of Love Hemp.

It’s perhaps the UK’s number one CBD and Hemp company.

What’s more, it recently signed a huge sponsorship deal with the extremely lucrative Ultimate Fighting Championship (UFC), as well as separately raising over £17 million to help increase its marketing globally.

It’s pretty good going for such a young company and shows just how determined it is to become a major player.

But, of course, you might be wondering...

Why is this relevant to the LOVE Pharma story?

Well, it’s because, as you might have guessed from the name, the group behind Love Hemp’s major moves is the same as the one behind LOVE Pharma.

It won’t come as a surprise, then, to learn that LOVE Pharma is already well funded to complete the next stages of its rollout, having secured over C$2.5 million to drive its global ambitions for the future. The same group also founded The Supreme Cannabis Company (TSX - FIRE) which was acquired in June 2021 by Canopy Growth Corporation (TSX - WEED) for $435,000,000 CAD.


Likewise, although LOVE Pharma’s initial sales focus will be on the UK and Europe…

It is only a matter of time before the firm starts to expand further afield – especially given its ambitions in the worlds of cannabis and psychedelics.

That said, even ahead of global expansion, there are many more present reasons to be excited when it comes to anticipating LOVE Pharma’s potential rise.

Distribution agreements are already being lined up and branding for the various products we’ve examined in this report is being finalized as we write.

And, when the company does pull the trigger, significant revenues are expected to start coming in at a startling rate – something few newly-listed businesses can boast.

It’s why, right now, smart investors have a brilliant opportunity to get in on the action well ahead of the game.

Now is the time to grab LOVE Pharma with both hands.

The firm is listing LOVE Pharma on the CSE, and plans to pursue an OTC listing and a listing in Frankfurt too to maximize the global pool of investors to which it has exposure.

In fact, when it comes to diversifying your portfolio, LOVE Pharma offers the perfect solution thanks to the diverse range of opportunities it has on the horizon.

Now is the time to grab it with both hands.


Leading product in the under-represented area of Female Sexual Dysfunction, with unique CBD upside.

Staggered broader product range addressing a wide range of sexual wellness issues like fertility, desire, and male issues.

Unique approach to booming CBD market from sub-lingual strip, with plans to expand into psychedelics in the future.

Management boasts a strong track record in forming companies and taking them to market with success.

Well-funded, with around C$2.5 million raised.

Strong position in the UK and Europe with distribution agreements being finalized, alongside global potential.

Plenty of catalysts on the horizon, providing multiple opportunities for valuation re-rate in line with larger peers.

RE

AS

ON

S W

HY

YO

U S

HO

UL

D

DIV

ER

SIF

Y Y

OU

R P

OR

TF

OL

IO

WIT

H L

OV

E P

HA

RM

A T

OD

AY


IMPORTANT NOTICE AND DISCLAIMERSPAID ADVERTISEMENTThis communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by LOVE Pharma to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred and sixteen thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICEReaders should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIESThis communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATIONNeither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated.


No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICEThe Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTSThis communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


INDEMNIFICATION/RELEASE OF LIABILITYBy reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMERBy reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTYAll trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.

AUTHOR: VALUETHEMARKETSValuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


https://www.valuethemarkets.com/terms-conditions/

https://www.valuethemarkets.com/disclaimer/

https://www.valuethemarkets.com/disclaimer/

love-pharma.com

cse:luv love pharma – driving a sexual health and

Documents